| Stock | Price | 52 Week Range | Marketcap | EPS | Dividend Yield | Chart (24H) | Sector | Employees | Last Updated |
|---|---|---|---|---|---|---|---|---|---|
 189981 KNSY | $0.0000 | 0.0000 | 0.00 | 0.00% | 0 | 6 years ago | |||
 458485 MIL | $0.0000 | 0.0000 | 0.00 | 0.00% | 0 | 6 years ago | |||
| $0.0000 | 0.0000 | 0.00 | 0.00% | 0 | 6 years ago | ||||
 Amedisys Inc AMED | $97.34 | 3.19B | 2.71 | 0.00% | Healthcare | 19,000 | 15 hours ago | ||
 225143 URS | $0.0000 | 0.0000 | 0.00 | 0.00% | 0 | 6 years ago |
In an ever-volatile market, finding stocks that consistently outperform can feel like searching for a diamond in the rough. Our proprietary Portfolio Grader offers an indispensable ally in this quest by spotlighting five gems that showcase prime earnings momentum. This is your golden opportunity to get ahead of the game and secure your financial future with stocks exhibiting exceptional fundamental performance.
Earnings Momentum is the superhero of stock performance metrics. High earnings momentum often translates to rapid appreciation in stock value, making these equities particularly appealing for growth-focused investors. According to our Portfolio Grader, which evaluates thousands of stocks every week, only the top performers make it to this coveted list.
Louis Navellier’s proprietary Portfolio Grader system assesses roughly 5,000 companies weekly, based on a plethora of fundamental and quantitative measures. The system awards each stock a letter grade from “A” (strong buy) to “F” (strong sell). This means the stocks highlighted here have been rigorously vetted and are top-tier in earnings momentum. You can explore this tool further to dig deep into the data that powers our recommendations.
What’s more? The diversity of the sectors these stocks hail from – biomaterials, industrial commodities, energy, healthcare, and engineering services – ensures a holistic portfolio that’s well poised to weather varying market conditions. This diversity allows you to mitigate risk while seizing opportunities across different industries.
Editor's Note: Analysis and insight for this article were originally sourced from our friends at InvestorPlace
Pioneering Biomaterials with a Massive ROI Potential
Kensey Nash (NASDAQ: KNSY) stands at the frontier of innovation in the medical field with its development and manufacturing of resorbable biomaterials. These products are not just revolutionary; they are in growing demand, thereby offering a robust ground for potential returns. Portfolio Grader awards KNSY an “A” in Operating Margin Growth, underlining its adeptness at turning sales into profit.
Operating Margin Growth is particularly crucial here because it signals the company’s efficiency in generating hard profits from its sales. By excelling in this metric, Kensey Nash demonstrates its ability to sustain and even accelerate its growth trajectory, making it a strategic pick for investors focused on medical innovation. For more detailed insights on KNSY, refer to the complete analysis available on Portfolio Grader.
Analyst Ratings for KNSY
| Metric | Value |
|---|---|
| Consensus Rating | Buy |
| Average Price Target | $34.00 |
| Current Price | NA |
| Potential Gain | NA |
| Number of Ratings | NA |
MIL: Dominating Industry Trends with Stunning Earnings Growth
If you are looking to gain exposure to global markets with a firm backed by robust financial health, MFC Industrial (NYSE: MIL) should be on your radar. MIL’s business revolves around the global sourcing and delivery of commodities and materials – a core component of worldwide economic activity.
Portfolio Grader’s high ratings in Earnings Growth, Cash Flow, and Operating Margin Growth imply that MIL isn’t just floating; it’s sailing strong through the economic winds. Commodities trading is a sector heavily influenced by global trends. As countries rebound from economic instabilities, MIL is set to accrue significant benefits, making it a solid pick for secure yet expansive growth. More information is available in the detailed Portfolio Grader analysis of MIL stock.
Analyst Ratings for MIL
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Buy | 10.59 PLN | 9.50 PLN | 11.09% | 6 |
High-Octane Returns Imminent – Why ALJ is an Energy Game Changer
Alon USA Energy (NYSE: ALJ) is more than just another player in the energy sector. As an independent refiner and marketer of petroleum products operating primarily in U.S. regions, ALJ is a powerful force.
Awarded an “A” in Earnings Growth, Analyst Earnings Revisions, and Equity by Portfolio Grader, ALJ’s credentials are impeccable. These high ratings highlight its strong market position and potential for generating hefty returns. For impact investors looking for a blend of reliability and growth in the often volatile energy sector, ALJ offers an attractive proposition. For a thorough breakdown of ALJ’s performance, check Portfolio Grader’s comprehensive analysis.
Analyst Ratings for ALJ
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Strong Buy | $133.43 | $115.30 | 15.72% | 7 |
Maximize Your Returns in Booming Health Care Industry
Amedisys (NASDAQ: AMED) is at the forefront of an expanding market, providing home health care and hospice services. The confluence of aging demographics and increasing preference for home health services has catapulted AMED into the limelight.
Exceling in Earnings Surprises and Cash Flow, Amedisys is not only meeting but exceeding expectations, maintaining robust cash reserves in the process. For investors, this translates into a strategic pick with a future brimming with growth opportunities driven by demographic trends and a strong track record of financial performance. Detailed insights are available in the Portfolio Grader’s complete analysis of AMED stock.
Analyst Ratings for AMED
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Hold | $100.67 – $101.00 | $97.60 – $97.98 | 2.97% – 3.48% | 5 – 3 |
Build a Fortified Portfolio with URS’s Diversified Earnings Growth
URS Corp. (NYSE: URS) is an engineering behemoth offering services across power, infrastructure, and industrial markets. Working in numerous essential sectors, URS boasts “A” ratings in Earnings Surprises and Cash Flow from Portfolio Grader, underscoring its operational efficiency and financial strength.
Infrastructure projects and government contracts are the lifeblood of URS, ensuring steady cash inflows and long-term growth potential. For investors who value stability coupled with the promise of substantial growth, URS presents an investment opportunity that’s difficult to overlook. Portfolio Grader’s complete analysis provides further details.
Analyst Ratings for URS
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Delisted | N/A | N/A | N/A | N/A |
Utilizing the insights from our exhaustive Portfolio Grader system, these five stocks are poised to provide you with stellar earnings momentum. They aren’t merely names on a list but keys to potential financial freedom, security, and a lasting legacy. Trust, transparency, and actionable insights are the pillars we build upon, ensuring you are always armed with the best information to steer your financial journey.
These stocks are more than investment opportunities; they are your ticket to outsmarting the market and securing life-changing returns. Dive deeper, stay informed, and seize these opportunities to elevate your investment strategy to unparalleled heights.